Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)

NCT04191616 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04191616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04191616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
August 6, 2020
Completion date
October 1, 2024
Enrollment
54 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma